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Introduction:  Previous  studies  have  shown  that  plasma  free  amino  acid (PFAA)  proﬁles  are  altered  in
cancer  patients  compared  with  healthy  controls.  A  multivariate  index  based  on  PFAAs  was  generated
from  a Japanese  dataset  and  has  been  previously  demonstrated  to be  clinically  valuable  for  discriminating
patients  in the  early  stages  of lung  cancer.  However,  it remains  unclear  whether  similar  PFAA  proﬁle
changes  occur  in cancer  patients  from  other  populations.  Therefore,  this  study  aimed  to  validate  the
performance  of  this  index  in  discriminating  lung  cancer  patients  from  controls  in the  Korean  population.
Methods:  Samples  were  collected  from  a total  of  142  Korean  subjects  (72 lung  cancer/70  controls)  for
this  study.  PFAAs  were  quantiﬁed  by high-performance  liquid  chromatography–electrospray  ionization-
mass  spectrometry,  and  the  clinical  performance  characteristics  of  the  amino  acid  multivariate  index
were  evaluated  across  cancer  stages  and  histological  types.
Results:  The  concentrations  of  several  PFAAs  were  signiﬁcantly  decreased  in  the  Korean  lung  cancer
patients  compared  with  the  controls.  Signiﬁcant  decreases  in  threonine,  citrulline,  histidine  and  trypto-
phan  and  increases  in  proline,  isoleucine,  phenylalanine  and  ornithine  were  observed,  which are  similar
to the  PFAA  changes  reported  by  a previous  Japanese  study.  The  area  under  the  receiver-operator  char-
acteristic curve  (AUC  of  the  ROC)  for the  index  was  0.80, and  similar  performances  were  demonstrated
for  the  different  histological  types.
Conclusions:  These  results  suggest  that  the  amino  acid multivariate  index previously  developed  from  a
Japanese  dataset  has  the  potential  to  aid in  the  early  detection  of  lung  cancers  of different  histological
types  in Korean  patients.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. IntroductionAmino acids play important roles as both basic metabolites and
hysiological regulators, and their metabolism is closely related to
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other metabolic networks, such as glucose and lipid metabolism.
Accordingly, their metabolism in organs is strictly regulated, and
the concentrations of plasma free amino acids (PFAAs), which
are abundant in the circulation and exchanged among all organ
systems, remain constant in a healthy state. However, numerous
studies have shown that various diseases, such as hepatic failure,
kidney failure, cancer, diabetes and Alzheimer’s disease, are able to
inﬂuence the concentrations of PFAAs [1–5], suggesting that they
may  be suitable biomarkers to discriminate these patients from
healthy subjects. For example, a previous study has reported that
his is an open access article under the CC BY-NC-ND license
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mong 61 potential metabolites, ﬁve branched-chain and aromatic
mino acids are biomarkers for predicting the future onset of type
 diabetes [6].
Many groups have reported that PFAA proﬁles differ signiﬁ-
antly in cancer patients, even among those with different types
f cancer [7–12]. The recently reported “AminoIndex Technology”
acilitates the evaluation of certain health conditions and the pos-
ibility of disease by analyzing the balance of PFAAs [13–15]. These
ublications have established amino acid multivariate indices using
he above technology and have clinically validated them for the
iscrimination of various cancer types, including lung, gastric,
olorectal, breast, prostate and gynecological cancers [13]. These
ndices compress the multidimensional PFAA proﬁle information
nto a single dimension and maximize differences between patients
nd controls. Using this technology, the “AminoIndex® Cancer
creening” service is now commercially available in Japan. The
obustness of the amino acid multivariate indices has been veri-
ed using large case-control datasets collected at multiple medical
nstitutes in Japan [16,17], and they have been shown to be able to
etect cancer regardless of the stage or histological type. However,
here are currently no data regarding the PFAA proﬁles in cancer
atients other than Japanese patients or of the differences in test
erformance characteristics among populations.
In Korea, approximately 218,000 people are diagnosed with can-
er annually. Approximately 72,000 persons died from cancer in
011, and this number is increasing [18]. Although national can-
er screening programs were initiated in 1999 in Korea, there is
o screening program for lung cancer, which is the leading cause
f cancer deaths in Korea [19]. Chest X-rays and sputum cytol-
gy are two screening tests that have been used to detect markers
f lung cancer, but neither is sufﬁciently sensitive to detect this
ancer at the early stages across different histological types. For
xample, chest X-rays are not always suitable for the early detec-
ion of cancer [20] and require highly skilled technicians to achieve
ufﬁcient accuracy. In addition, it has been reported that sputum
ytology is useful only for the detection of squamous cell carcinoma
ut not adenocarcinoma [20]. Although low-dose helical computed
omography (LDCT) has been recently reported to be a new screen-
ng method, it may  produce a high rate of false positives [21] and
xposes subjects to radiation. Therefore, there is an urgent need for
ew, non-invasive methods to detect lung cancer at an early stage
or all histological subtypes.
In the present study, we focus on a previously developed amino
cid multivariate index for lung cancer, and we aimed to investigate
hether the PFAA proﬁle changes in Korean lung cancer patients
able 1
linical characteristics of the subjects.
Number Total 
(Male, female) 
Age,  year Mean ± SD 
Range 
BMI,  kg/m2 Mean ± SD 
Range 
Smoking status Never 
Ex  
Current 
Unknown 
Clinical stage I 
II  
III  
IV  
Histology Adenocarcinoma 
Squamous cell carcinoma 
Other NSCLC 
Unknown 
igniﬁcant differences were evaluated by Student’s t-test (*P < 0.05). 90 (2015) 522–527 523
are similar to those in Japanese patients and to evaluate the perfor-
mance of the index for the detection of lung cancer across different
stages and histological types in Korean patients.
2. Research design and methods
2.1. Methods
2.1.1. Ethics
The study was  conducted in accordance with the Declaration of
Helsinki, and the protocol was  approved by the ethics committees
of Konkuk University Medical Center, Inha National University Hos-
pital, Chonnam National University Hwasun Hospital, Chungnam
National University Hospital, Hallym University Medical Center,
Kyungpook National University Medical Center, Pusan National
University Hospital, and Kosin University Gospel Hospital. All sub-
jects gave their written informed consent for inclusion before
participating in the study. All data were analyzed anonymously
throughout the study.
2.1.2. Subjects
The participants comprised Korean patients who had been his-
tologically diagnosed with lung cancer at any of the 8 included
Korean medical hospitals (n = 75), as well as sex- and age-matched
control subjects without cancer (n = 80).
2.1.3. Quantiﬁcation of plasma amino acid concentration
Blood samples (5 ml)  were collected from the forearm veins in
the morning after overnight fasting into tubes containing ethylene-
diaminetetraacetic acid (EDTA) and immediately placed on ice.
Plasma was prepared by centrifugation at 3000 rpm at 4 ◦C for
15 min  and was  then stored at −80 ◦C until analysis. The plasma
samples were deproteinized using acetonitrile to a ﬁnal concen-
tration of 80% and subjected to precolumn derivatization followed
by high-performance liquid chromatography (HPLC)–electrospray
ionization (ESI)-mass spectrometry (MS) for amino acid quantiﬁca-
tion, as described previously [22–24]. The 19 amino acids that were
quantiﬁed included the following: alanine (Ala), arginine (Arg),
asparagine (Asn), citrulline (Cit), glutamine (Gln), glycine (Gly),
histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methi-
onine (Met), ornithine (Orn), phenylalanine (Phe), proline (Pro),
serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), and
valine (Val). The concentrations of the amino acids in the plasma
are expressed in M,  and the percentages of the amino acid con-
centrations compared with the sum of all of the amino acids (the
Lung cancer Controls P
72 70
(51, 21) (44, 26)
65.6 ± 9.2 63.2 ± 8.9 NS
45–82 39–78
22.2 ± 3.4 23.3 ± 2.3 0.042*
13.9–29.5 17.8–28.2
19 34
13 25
40 8
0 3
14
5
21
32
37
30
4
1
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Table 2
Comparison of plasma amino acid concentrations between cancer patients and
healthy controls.
Lung Cancer Controls
Amino acids ( M)  Mean SD Mean SD AUC  P
Thr 109.8 30.6 127.2 28.8 0.340 <0.001 ***
Ser 110.4 27.3 112.6 21.2 0.464 0.459
Asn 44.4 11.0 49.2 9.1 0.352 0.002 **
Gln 556.8 115.2 603.9 69.9 0.337 <0.001 ***
Pro 165.0 48.9 152.3 39.1 0.572 0.140
Gly 204.8 55.2 225.2 44.7 0.383 0.016 *
Ala 357.0 124.2 383.0 86.7 0.386 0.019 *
Cit 28.9 9.0 37.1 10.3 0.261 <0.0001 ****
Val 222.0 43.9 241.1 43.7 0.370 0.008 **
Met  25.8 6.7 28.3 5.1 0.361 0.004 **
Ile 69.6 16.4 68.6 14.4 0.503 0.958
Leu 123.9 29.1 133.4 26.6 0.385 0.018 *
Tyr 68.4 15.7 70.3 12.7 0.469 0.523
Phe 68.5 16.3 63.4 9.6 0.571 0.145
His 66.8 13.8 82.6 10.3 0.180 <0.0001 ****
Trp 48.9 10.7 59.3 10.9 0.222 <0.0001 ****
Orn 70.3 24.3 68.1 18.9 0.517 0.736
Lys 183.5 42.5 198.5 38.3 0.384 0.017 *
Arg 90.4 25.8 100.2 20.2 0.374 0.009 **
Signiﬁcant differences were determined by the Mann–Whitney U-test.
* P < 0.05.
**24 H.J. Kim et al. / Lung 
elative amino acid value) are expressed by the following previ-
usly described equation:
2i,j =
Xi.j∑
kXi,k
here X2i ,j is the relative amino acid value of the j-th amino acid
f the i-th subject, and Xi,j is the plasma concentration (M)  of the
-th amino acid of the i-th subject.
.1.4. Calculation of amino acid multivariate index scores
The PFAA proﬁles of the subjects were evaluated with a previ-
usly established amino acid multivariate index. These indices are
ogistic regression functions that discriminate lung cancer patients
rom healthy controls. Index-1, which is used in the “AminoIndex®
ancer Screening” service in Japan, consists of Ser, Gln, Ala, His, Orn
nd Lys [17,25], and index-2, which has been previously reported,
omprises Ala, Val, Ile, His, Trp and Orn [16].
.2. Statistical analysis
.2.1. Mean and standard deviation (SD)
The mean amino acid concentrations ± SD were calculated to
etermine the overall PFAA proﬁles for both the controls and
atients.
.2.2. Mann–Whitney U-test
The Mann–Whitney U-test was used to evaluate the differences
n the PFAA proﬁles between the controls and patients.
.2.3. ROC curve analysis
Receiver-operator characteristic (ROC) curve analyses were
erformed to evaluate the performances of both the PFAA concen-
rations and the multivariate PFFA index in discriminating between
atients and controls. The patient labels were ﬁxed as positive class
abels. Thus, a value <0.5 for the area under the ROC curve (AUC
f the ROC) indicated that the amino acid level was  lower in the
atients than in the controls, whereas an AUC of the ROC of >0.5
ndicated a higher level in the controls. A 95% conﬁdence interval
95% CI) for the AUC of the ROC for the discrimination of patients
ased on amino acid concentrations and relative values was  also
stimated, as described by Hanley and McNeil [26].
.2.4. Software
All of the analyses were performed using GraphPad Prism 6
GraphPad Software, La Jolla, CA, USA).
. Results
.1. Characteristics of Korean subjects in this study
Between February 2013 and November 2013, 80 lung cancer
atients and 75 controls were enrolled in this study. Subjects whose
lood was collected during the afternoon were excluded from the
nalysis based on previous study data indicating the circadian ﬂuc-
uations of PFAAs [27]. Therefore, 72 lung cancer patients and 70
ontrols were analyzed in total. Table 1 summarizes the charac-
eristics of the subjects in this study. No signiﬁcant differences in
ex distribution or age were observed between the lung cancer
atients and controls. The body mass index (BMI) of the patients
as signiﬁcantly lower than that of the controls.
Disease stages were determined according to the Sixth Edition
f the International Union Against Cancer (UIGC) Tumor-Node-
etastasis (TNM) Classiﬁcation of Malignant Tumors. The fractions
f patients at each stage were as follows: ∼20% stage I, ∼5% stageP< 0.01.
*** P < 0.001.
**** P < 0.0001.
II, ∼30% stage III, and ∼45% stage IV. The patients were also sub-
divided according to histological tumor type. Approximately 50%
of the patients had adenocarcinoma, and approximately 40% had
squamous cell carcinoma.
3.2. PFAA proﬁles of lung cancer patients
To compare the PFAA proﬁles between the lung cancer patients
and controls, the amino acids concentrations were quantiﬁed, and
the AUCs of the ROC for each amino acid were determined (Table 2).
Signiﬁcant decreases in the concentrations of Thr, Asn, Gln, Gly, Ala,
Cit, Val, Met, Leu, His, Trp, Lys and Arg were observed in the lung
cancer patients. Because a global decrease in the PFAA concentra-
tions was observed, ROC analysis using the relative values of each
amino acid was conducted (Fig. 1A). Comparisons of the relative
values revealed signiﬁcant decreases in the Thr, Cit, His and Trp
levels and signiﬁcant increases in the Pro, Ile, Phe and Orn levels.
The PFAA proﬁles across the clinical stages were also compared
(Fig. 1B). In the early stages of lung cancer (stages I and II), signiﬁ-
cant decreases in the relative levels of Thr, Asn, Cit, Met, His and Trp
and signiﬁcant increases in the relative levels of Pro and Ile were
observed. Signiﬁcant decreases in the relative levels of Thr, Cit, His
and Trp and signiﬁcant increases in the Pro, Ile, Phe and Orn levels
were observed during the late stages (stages III and IV).
3.3. Clinical performance evaluation
The amino acid multivariate index for the discrimination of lung
cancer patients from controls includes the following six amino
acids: Ser, Gln, Ala, His, Orn and Lys. This index (index-1) is used
by the “AminoIndex® Cancer Screening” service in Japan and was
generated from logistic regression models using PFAA data col-
lected from a Japanese multisite study consisting of 996 controls
and 200 lung cancer patients [25]. To evaluate the performance of
this index in Korean subjects, the ROC curve of the index for dis-
criminating lung cancer patients from controls in the current study
is illustrated in Fig. 2. The AUC of the ROC reached 0.80 (95% CI:
0.72–0.87). The AUC of ROC of another function (index-2), which
H.J. Kim et al. / Lung Cancer 90 (2015) 522–527 525
Fig. 1. PFAA proﬁles of Korean lung cancer patients.
The axes show the AUC of the ROC for the relative value of each amino acid to discrim-
inate lung cancer patients from controls. The bold black line indicates the point at
which the AUC of the ROC = 0.5. (A) PFAA proﬁles of lung cancer patients. Signiﬁcant
increases in Pro, Ile, Phe, and Orn and signiﬁcant decreases in Thr, Cit, His, and Trp
were observed. (B) Comparison of the PFAA proﬁles of lung cancer patients across
clinical stages. The blue line corresponds with the early stages of cancer (stages I
and II), during which signiﬁcant increases in Pro and Ile and signiﬁcant decreases in
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Fig. 2. The ROC curve of the index for discriminating lung cancer patients.
The  ROC curve of the indices for distinguishing lung cancer patients from controls
is  shown. The AUCs of the ROC were 0.80 (95% CI: 0.72–0.87) and 0.72 (95% CI:
0.72–0.87) for index-1 and index-2, respectively.
Fig. 3. ROC curves of the index subgrouped by cancer stage and histological type.
(A) ROC curves for each cancer stage for the dataset of this study. Stages I and II:
AUC of the ROC = 0.70 (95% CI: 0.57–0.83); stage III: AUC of the ROC = 0.89 (95% CI:
0.82–0.96); and stage IV: AUC of the ROC = 0.79 (95% CI: 0.70–0.88). (B) ROC curveshr,  Asn, Cit, Met, His and Trp were observed. The red line indicates the later stages
f  cancer (stages III and IV), during which signiﬁcant increases in Pro, Ile, Phe and
rn  and signiﬁcant decreases in Thr, Cit, His and Trp were observed.
as also been reported to discriminate lung cancer patients in a
revious Japanese study, was 0.72 (95% CI: 0.64–0.81).
.4. Performance of index across clinical stages and histological
ypes
To further investigate the performance of the index-1 in dis-
riminating lung cancer patients across different clinical stages and
istological tumor types, the AUCs of the ROC for each stage and
ach histological type were compared (Fig. 3) and were found to be
.70 (95% CI: 0.57–0.83) for the stages I and II patients, 0.89 (95%
I: 0.82–0.96) for the stage III patients and 0.79 (95% CI: 0.70–0.88)
or the stage IV patients. In addition, this index demonstrated a
imilar performance for both adenocarcinoma and squamous cell
for  the histological types for the dataset of this study. Adenocarcinoma: AUC  of the
ROC = 0.78 (95% CI: 0.70–0.87); and squamous cell carcinoma: AUC of the ROC = 0.84
(95% CI: 0.75–0.92).
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arcinoma, with AUCs of the ROC of 0.78 (95% CI: 0.70–0.87) for
denocarcinoma and 0.84 (95% CI: 0.75–0.92) for squamous cell
arcinoma.
. Discussion
The present study was conducted to conﬁrm the performance of
 previously established amino acid multivariate index developed
n Japan for use in the evaluation of lung cancer in Korean subjects.
o conﬁrm that differences between the datasets did not bias the
esults, the subjects’ demographics were compared. The average
ge and BMI  for the Japanese dataset used for the development of
he index (control: 996 and cancer: 200) were 63.2 year for the con-
rols and 65.0 year for the patients and 22.9 kg/m2 for the controls
nd 22.5 kg/m2 for the patients, respectively [13]. These charac-
eristics were similar to those of the Korean subjects enrolled in
he current study. However, the percentage of early stage patients
stages I and II) in this study was much lower (approximately 25%)
ompared with the Japanese study (approximately 60%).
Numerous clinical studies performed by other groups have also
emonstrated cancer-related PFAA proﬁles, suggesting that the
etabolic alterations in various cancers induce changes in PFAA
evels; however, there are some discrepancies among results [7,12].
hese differences may  be due to the limited sizes of datasets or to
ifferences in specimen processing procedures after blood samples
ere drawn. Several amino acids, such as Orn and Arg, undergo
apid ex vivo degradation at room temperature, and their levels
igniﬁcantly differ depending on whether blood samples are imme-
iately cooled or are stored at room temperature for a period of time
28]. In the current study, the blood samples were cooled immedi-
tely within 1 min  after blood collection and for at least 15 min
efore plasma separation so that the amino acids remained stable.
We found a global decrease in the following 13 amino acids in
he lung cancer patients compared with the controls: Thr, Asn, Gln,
ly, Ala, Cit, Val, Met, Leu, His, Trp, Lys and Arg. We  have previously
eported that the overall PFAA concentration in patients with stage
V lung cancer is lower than that in stage I patients [13], indicat-
ng that the high percentage of later-stage cancers in the Korean
ataset may  have inﬂuenced the decreased PFAA levels. It is also
nown that protein malnutrition causes decreased PFAA concen-
rations [29]. In this study, approximately 60% of the patients had
erum albumin levels of lower than 4.0 g/dL (standard value) (data
ot shown), suggesting that protein malnutrition may  have inﬂu-
nced their lower PFAA levels. Since albumin data was  available
nly for a limited number of subjects in this study, further stud-
es are required to elucidate the mechanism behind the PFAA level
ecrease by studying PFAA changes in an albumin level matched
tudy population.
To further evaluate the individual amino acid changes between
he Korean and Japanese datasets, we compared the amino acid lev-
ls in terms of the total percentage of all amino acids. We  detected
igniﬁcant decreases in the relative levels of Thr, Cit, His and Trp
nd increases in the relative levels of Pro, Ile, Phe and Orn. These
hanges are similar to those of the previously reported Japanese
ataset [13]. Signiﬁcant decreases in the Thr, Cit, His and Trp levels
nd decreases in the Pro and Ile levels were observed in the patients
ith stages I and II lung cancer, indicating that the PFAA proﬁles of
atients with this type of cancer are altered from the early stages.
he signiﬁcant increases in the Phe and Orn levels observed only
uring the later stages (stages III and IV) have also been similarly
eported in a previous Japanese study [13].The mechanism behind the PFAA proﬁle alterations observed in
ancer patients is unknown. Indoleamine-2,3-dioxygenase (IDO),
he ﬁrst enzyme in the human kynurenine Trp metabolic pathway,
as been reported to be overexpressed in various tumor types [30], 90 (2015) 522–527
potentially contributing to the decrease in the plasma Trp concen-
tration. In addition, an in vivo study using tumor-bearing mice has
demonstrated that some amino acids, such as Ala, Gly and Ser, may
be produced by tumors [31]. Recently, a study has suggested that
PFAA proﬁles can be inﬂuenced by metabolic changes occurring
in various organs without tumor tissue. Our group has reported
that High-mobility group box 1 protein (HMGB1), which is an
autophagy-inducing stress protein secreted from tumors, induces
muscles to supply glutamine to cancer cells as an energy source
[32]. However, these results are not sufﬁcient to explain why alter-
ations in PFAA proﬁles can be observed during the early stages of
cancer. Further clariﬁcation of the relationship between amino acid
metabolism throughout the entire body and cancer development
is required to understand these mechanisms more precisely.
In this study, the performance of the amino acid multivari-
ate index for lung cancer, which was previously established and
validated in a Japanese case-control dataset, was  veriﬁed in an inde-
pendent Korean dataset. The AUC of the ROC for the amino acid
multivariate index in the Korean dataset reached 0.80. This value
is similar to the AUC of the ROC previously reported for a Japanese
dataset (0.777; 95% CI: 0.718–0.836) consisting of 421 controls and
85 lung cancer patients [17]. In addition, the AUC of the ROC for
another index (index-2) that has been previously reported to dis-
criminate lung cancer patients was  0.72 (0.731 for the Japanese
dataset [17]), suggesting that the changes in the PFAA proﬁles of
lung cancer patients are similar between the Korean and Japanese
populations.
There is currently no test available that can detect all of the
histological types of lung cancer. Although tumor markers are
presently used to aid in the detection of lung cancer, these mark-
ers are not always useful due to their high histological speciﬁcity.
For example, cytokeratin fragment (CYFRA) and squamous cell car-
cinoma antigen (SCC) are speciﬁc to squamous cell carcinoma,
pro-gastrin-releasing peptide (ProGRP) and neuron speciﬁc enolase
(NSE) are speciﬁc to small cell lung cancer, and carcinoembryonic
antigen (CEA) is not speciﬁc to any particular histological type of
cancer [33]. In addition, these tumor markers do not exhibit a sufﬁ-
cient ability to discriminate cancer patients at early stages. We  have
previously demonstrated that the amino acid multivariate index
can discriminate lung cancer patients from controls regardless of
the histological type or clinical stage, indicating that it is more
sensitive than any of the currently used tumor markers [17]. We
veriﬁed these results in the current study and found that this index
has a signiﬁcant ability to discriminate lung cancer patients from
those in the early stages (stages I and II), independent of the his-
tological type (adenocarcinoma or squamous cell carcinoma). The
majority of the lung cancer patients in this study were either ade-
nocarcinoma or squamous cell carcinoma, and the sample size for
other histological types was  too small to evaluate the performance
of the index. Regarding other lung cancer types such as small cell
lung cancer, we have previously reported that the performance of
the index was similar to adenocarcinoma and squamous cell carci-
noma [16]. Furthermore, the tendency for the AUC of the ROC for
squamous cell carcinoma (0.84) to be higher than that for adeno-
carcinoma (0.78) was  also observed in the Japanese dataset [17].
Collectively, these results suggest that this index has the potential
to aid in the early detection of lung cancer of different histological
types in both the Korean and Japanese populations.
In conclusion, this study demonstrated that there were signif-
icant differences in the PFAA proﬁles of the Korean lung cancer
patients compared with the controls and that these differences are
similar to those reported in a previous Japanese study. Our results
also demonstrate that the amino acid multivariate index developed
from the Japanese dataset can discriminate Korean lung cancer
patients from healthy controls. Although additional prospective
validation in a larger population with longitudinal follow-up to
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